Xcell Initiates New Collaborations with UCSF Researchers
News Sep 23, 2016
Xcell Biosciences has announced that it has extended its collaborative work with the University of California, San Francisco (UCSF) to include working with three principal investigators on pilot studies using Xcell’s Avatar cell culture system and proprietary analytics platform. The work will determine if large scale RNA profiling from peripheral blood and other patient-derived sample sources cultured in the Avatar System and correlated to clinical outcomes can predict a patient’s response to first or second line treatments in prostate, bladder and kidney cancers.
Charles J. Ryan, MD, Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center, has been collaborating with Xcell for several years on a number of projects. The latest involves studying the relationship between genomic variation in prostate cancer patient samples and response to treatment, including in patients who have developed resistance to standard of care therapies.
“We are particularly enthusiastic about the opportunity to use the Avatar system to compare results from liquid biopsies to actual tissue biopsies,” said Dr. Ryan. “We also are optimistic about the ability to use the system to look at broad-scale genomic alterations in cancer patients without the necessity for looking at circulating tumor cells, cell free DNA or tissue biopsies. Xcell’s system offers the opportunity to look at different types of analysis all with one blood draw – for example, potential relationships between immunology, androgen receptors, and DNA repair in prostate cancer.”
Terry Friedlander, MD, Associate Clinical Professor of Medicine at UCSF, is collaborating on studies involving prostate and bladder cancer. “We are excited about this collaboration and the potential ability to use the Avatar system as an immunologic springboard,” he said. “Predicting treatment response is a huge unanswered question in oncology in general. If the Avatar system can keep the cells in the same state that they were in the body, we may get a more accurate read on the activation status of the immune system and determine markers that might help predict response to treatment.”
UCSF medical oncologist Won Kim, MD, who is leading a study in kidney cancer, added: “Kidney cancer is a disease where we have a real shortage of predictive and prognostic biomarkers. For this pilot study, we’re hopeful that we will show that the data generated from Xcell’s platform will help us identify which patients with renal cell cancer are more likely to respond to tyrosine kinase inhibitors or immunotherapy. We all want these feasibility studies to succeed because there are so many cancers where tissue is just not easy to access.”
James Lim, PhD, Chief Scientific Officer at Xcell Biosciences, commented, “We are delighted to continue our collaborative work with UCSF, a leading center for cancer clinical research, on these new studies. We believe our RNA-based whole transcriptome approach to liquid biopsy will enable us to generate unique gene expression signatures that will predict a patient’s response to a given therapeutic. Our goal is to ultimately demonstrate evidence that the Avatar system’s physiologically relevant microenvironments can provide unparalleled and previously unavailable diagnostic insights enabling oncologists to treat patients more effectively and also at the right time.”
Watching Stem Cells Repair Spinal Cord in Real TimeNews
Clues to the reversal of brain and spine injury.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.